From 9299c56369cdda07bbf916dc14f926b2714a6d7d Mon Sep 17 00:00:00 2001 From: jonas-fuchs <78491186+jonas-fuchs@users.noreply.github.com> Date: Thu, 1 Oct 2026 11:25:03 +0000 Subject: [PATCH] chore(herpesdrg): autobump source outputs --- databases/herpesdrg/output/metadata.json | 4 +- .../herpesdrg/output/non-migrated-rules.txt | 3 + databases/herpesdrg/output/rules.tsv | 67 ++++++++++++++----- databases/manifest.json | 4 +- 4 files changed, 58 insertions(+), 20 deletions(-) diff --git a/databases/herpesdrg/output/metadata.json b/databases/herpesdrg/output/metadata.json index 5bffa9b..e066048 100644 --- a/databases/herpesdrg/output/metadata.json +++ b/databases/herpesdrg/output/metadata.json @@ -6,9 +6,9 @@ "publication_pmid": "39192205", "website": "https://github.com/ojcharles/herpesdrg-db", "description": "Comprehensive resource for human herpesvirus antiviral drug resistance genotyping.", - "maintainer_update": "2026-07-05", + "maintainer_update": "2026-09-29", "license": "MIT", - "tsv_checksum": "sha256:59f3c0fb4cc9ff8e3f013294de7b59fe956b930fe68ea5a94811d17b23c85fe6", + "tsv_checksum": "sha256:6d20f27b11b8a6616fc6b7f09d7825addaa8fbbf5d5f8a94a445ce818140dc5a", "interpretation_algorithms": [ { "name": "drug_groups", diff --git a/databases/herpesdrg/output/non-migrated-rules.txt b/databases/herpesdrg/output/non-migrated-rules.txt index eede68e..654d98b 100644 --- a/databases/herpesdrg/output/non-migrated-rules.txt +++ b/databases/herpesdrg/output/non-migrated-rules.txt @@ -24,6 +24,7 @@ status_not_active 1751 HCMV UL54 A543V UL54 M460I O co-occurs with M460I which c status_not_active 496 HCMV UL54 A626V O Anecdotal status_not_active 499 HCMV UL54 A631G O Anecdotal status_not_active 509 HCMV UL54 A688V O Anecdotal +status_not_active 48 HCMV UL54 A692S O S Chou flagged that there is a 2004 erratum which invalidates this entry and recommendation is to remove it. status_not_active 511 HCMV UL54 A693T O Anecdotal status_not_active 521 HCMV UL54 A885S O Anecdotal status_not_active 522 HCMV UL54 A885T O Anecdotal @@ -351,9 +352,11 @@ unparseable_mutation 81 HCMV UL54 del981-982 A failed_part=del981-982 unparseable_mutation 221 HCMV UL54 del981-982 A failed_part=del981-982 unparseable_mutation 431 HCMV UL54 del981-982 A failed_part=del981-982 unparseable_mutation 2050 HCMV UL54 del981-982 A failed_part=del981-982 +unparseable_mutation 2095 HCMV UL54 del981-982 A failed_part=del981-982 unparseable_mutation 563 HCMV UL56 del445-447 UL56 E485G A failed_part=del445-447 unparseable_mutation 569 HCMV UL56 del789-791 A failed_part=del789-791 unparseable_mutation 277 HCMV UL97 del355 A failed_part=del355 +unparseable_mutation 2112 HCMV UL97 del381-382 A failed_part=del381-382 unparseable_mutation 107 HCMV UL97 del590-593 A failed_part=del590-593 unparseable_mutation 174 HCMV UL97 del595-603 A failed_part=del595-603 unparseable_mutation 181 HCMV UL97 del600 A failed_part=del600 diff --git a/databases/herpesdrg/output/rules.tsv b/databases/herpesdrg/output/rules.tsv index 90f2d0a..95e852d 100644 --- a/databases/herpesdrg/output/rules.tsv +++ b/databases/herpesdrg/output/rules.tsv @@ -1889,15 +1889,18 @@ UL52 NC_001806 902 N T amenamevir 6 doi:doi.org/10.1128/AAC.00494-21 HerpesDRG UL52 NC_001806 902 N T foscarnet 1 doi:doi.org/10.1128/AAC.00494-21 HerpesDRG Test method: PRA, Rule created at: 22/12/2021 UL27 NC_006273 22 E * maribavir 2 doi:doi.org/10.1128/AAC.01177-08 HerpesDRG Test method: SEAP, Rule created at: 17/11/2019 UL27 NC_006273 153 W R maribavir 1.7 doi:doi.org/10.1128/AAC.01177-08 HerpesDRG Test method: SEAP, Rule created at: 17/11/2019 -UL27 NC_006273 193 L F maribavir 2.6 doi:doi.org/10.1128/AAC.01177-08 HerpesDRG Test method: SEAP, Rule created at: 17/11/2019 +UL27 NC_006273 167 Q R maribavir 1.1 doi:doi.org/10.1016/j.antiviral.2026.106536 HerpesDRG Test method: SEAP, Rule created at: 25/09/2026 +UL27 NC_006273 193 L F maribavir 2.3 doi:doi.org/10.1128/AAC.01177-08,doi:doi.org/10.1016/j.antiviral.2026.106536 HerpesDRG Fold IC50 values: 2.6, 2; mean displayed, Test method: SEAP, Rule created at: 17/11/2019,25/09/2026 UL27 NC_006273 233 R S maribavir 8.54 doi:doi.org/10.1016/j.antiviral.2012.05.013,doi:doi.org/10.1128/jvi.78.13.7124-7130.2004 HerpesDRG Fold IC50 values: 1.8, 7.2, 27, 2, 4.7; mean displayed, Test method: SEAP,PRA or SEAP,PRA, Rule created at: 17/11/2019,07/08/2023, Co-mutation context in source: UL97:L337M,UL97:V353A,UL97:S334G UL27 NC_006273 269 A T maribavir 2 doi:doi.org/10.1128/AAC.01177-08 HerpesDRG Test method: SEAP, Rule created at: 17/11/2019 +UL27 NC_006273 317 L V maribavir 2 doi:doi.org/10.1016/j.antiviral.2026.106536 HerpesDRG Test method: SEAP, Rule created at: 25/09/2026 UL27 NC_006273 335 L P ganciclovir 1.2 doi:doi.org/10.1128/jvi.77.21.11499-11506.2003 HerpesDRG Test method: PRA, Rule created at: 17/11/2019 UL27 NC_006273 335 L P maribavir 23 doi:doi.org/10.1128/jvi.77.21.11499-11506.2003 HerpesDRG Test method: PRA, Rule created at: 17/11/2019 UL27 NC_006273 353 V A maribavir 16 doi:doi.org/10.1128/AAC.01177-08 HerpesDRG Test method: SEAP, Rule created at: 07/08/2023 UL27 NC_006273 353 V E maribavir 2.1 doi:doi.org/10.1128/AAC.01177-08 HerpesDRG Test method: SEAP, Rule created at: 17/11/2019 UL27 NC_006273 362 W * maribavir 2.2 doi:doi.org/10.1128/AAC.01177-08 HerpesDRG Test method: SEAP, Rule created at: 17/11/2019 UL27 NC_006273 362 W R maribavir 1.95 doi:doi.org/10.1128/AAC.01177-08,doi:doi.org/10.1128/jvi.78.13.7124-7130.2004 HerpesDRG Fold IC50 values: 1.9, 2; mean displayed, Test method: SEAP,PRA, Rule created at: 17/11/2019,07/08/2023 +UL27 NC_006273 375 A T maribavir 0.9 doi:doi.org/10.1016/j.antiviral.2026.106536 HerpesDRG Test method: SEAP, Rule created at: 25/09/2026 UL27 NC_006273 415 C * maribavir 3.5 doi:doi.org/10.1128/jvi.78.13.7124-7130.2004 HerpesDRG Test method: PRA, Rule created at: 17/11/2019, Co-mutation context in source: UL27:A406V UL27 NC_006273 426 L F maribavir 2.2 doi:doi.org/10.1128/AAC.01177-08 HerpesDRG Test method: SEAP, Rule created at: 17/11/2019 UL27 NC_006273 448 R P maribavir 1.5 doi:doi.org/10.1016/j.antiviral.2012.05.013 HerpesDRG Test method: SEAP, Rule created at: 07/08/2023 @@ -2031,6 +2034,9 @@ UL54 NC_006273 488 P R ganciclovir 5.5 doi:doi.org/10.1128/AAC.00334-11,doi:do UL54 NC_006273 495 N K cidofovir 1.45 doi:doi.org/10.1177/135965350601100416,doi:doi.org/10.1016/j.antiviral.2016.12.003,doi:doi.org/10.1016/j.antiviral.2008.09.009 HerpesDRG Fold IC50 values: 1.1, 1, 1.2, 2.5; mean displayed, Test method: PRA or SEAP,SEAP,PRA, Rule created at: 17/11/2019,16/03/2020,14/08/2023, Co-mutation context in source: UL54:Q738R UL54 NC_006273 495 N K foscarnet 4.02 doi:doi.org/10.1177/135965350601100416,doi:doi.org/10.1016/j.antiviral.2016.12.003,doi:doi.org/10.1016/j.antiviral.2008.09.009,doi:doi.org/10.1016/j.jviromet.2005.01.005 HerpesDRG Fold IC50 values: 3.4, 2.6, 3.5, 5.6, 5; mean displayed, Test method: PRA or SEAP,SEAP,PRA,Functional enzyme kinetic assay, Rule created at: 17/11/2019,16/03/2020,14/08/2023,18/08/2025, Co-mutation context in source: UL54:Q738R UL54 NC_006273 495 N K ganciclovir 1.275 doi:doi.org/10.1177/135965350601100416,doi:doi.org/10.1016/j.antiviral.2016.12.003,doi:doi.org/10.1016/j.antiviral.2008.09.009 HerpesDRG Fold IC50 values: 1.1, 1.3, 1.7, 1; mean displayed, Test method: PRA or SEAP,SEAP,PRA, Rule created at: 17/11/2019,16/03/2020,14/08/2023, Co-mutation context in source: UL54:Q738R +UL54 NC_006273 498 N S cidofovir 1.8 doi:doi.org/10.1016/j.antiviral.2025.106340 HerpesDRG Test method: SEAP, Rule created at: 25/09/2026 +UL54 NC_006273 498 N S foscarnet 1.7 doi:doi.org/10.1016/j.antiviral.2025.106340 HerpesDRG Test method: SEAP, Rule created at: 25/09/2026 +UL54 NC_006273 498 N S ganciclovir 1.7 doi:doi.org/10.1016/j.antiviral.2025.106340 HerpesDRG Test method: SEAP, Rule created at: 25/09/2026 UL54 NC_006273 500 K N cidofovir 3.5 doi:doi.org/10.1128/aac.00334-11,doi:doi.org/10.1016/j.antiviral.2022.105328 HerpesDRG Fold IC50 values: 3, 2.4, 5.8, 2.8; mean displayed, Test method: PRA, Rule created at: 17/11/2019,16/03/2020,11/08/2025, Co-mutation context in source: UL54:S585A UL54 NC_006273 500 K N foscarnet 1.975 doi:doi.org/10.1128/aac.00334-11,doi:doi.org/10.1016/j.antiviral.2022.105328 HerpesDRG Fold IC50 values: 1.2, 2.7, 1.2, 2.8; mean displayed, Test method: PRA, Rule created at: 17/11/2019,16/03/2020,11/08/2025, Co-mutation context in source: UL54:S585A UL54 NC_006273 500 K N ganciclovir 2.7 doi:doi.org/10.1128/aac.00334-11,doi:doi.org/10.1016/j.antiviral.2022.105328 HerpesDRG Fold IC50 values: 3.2, 2.4, 2.9, 2.3; mean displayed, Test method: PRA, Rule created at: 17/11/2019,16/03/2020,11/08/2025, Co-mutation context in source: UL54:S585A @@ -2067,9 +2073,9 @@ UL54 NC_006273 513 K R aciclovir 3.6 doi:doi.org/10.1016/j.antiviral.2021.1051 UL54 NC_006273 513 K R cidofovir 12 doi:doi.org/10.1128/AAC.03214-14,doi:doi.org/10.1016/j.antiviral.2021.105181 HerpesDRG Fold IC50 values: 10, 14; mean displayed, Test method: SEAP, Rule created at: 17/11/2019,21/12/2021 UL54 NC_006273 513 K R foscarnet 1.1 doi:doi.org/10.1128/AAC.03214-14 HerpesDRG Test method: SEAP, Rule created at: 17/11/2019 UL54 NC_006273 513 K R ganciclovir 3.7 doi:doi.org/10.1128/AAC.03214-14 HerpesDRG Test method: SEAP, Rule created at: 17/11/2019 -UL54 NC_006273 515 D E cidofovir 1.6 doi:doi.org/10.1016/j.jcv.2015.06.090 HerpesDRG Test method: PRA, Rule created at: 14/08/2023 -UL54 NC_006273 515 D E foscarnet 2.85 doi:doi.org/10.1182/blood.V96.9.3286,doi:doi.org/10.1016/j.jcv.2015.06.090 HerpesDRG Fold IC50 values: 4.6, 1.1; mean displayed, Test method: PRA or SEAP,PRA, Rule created at: 17/11/2019,14/08/2023, Co-mutation context in source: UL54:L516M;I521T -UL54 NC_006273 515 D E ganciclovir 2.55 doi:doi.org/10.1182/blood.V96.9.3286,doi:doi.org/10.1016/j.jcv.2015.06.090 HerpesDRG Fold IC50 values: 2.7, 2.4; mean displayed, Test method: PRA or SEAP,PRA, Rule created at: 17/11/2019,14/08/2023, Co-mutation context in source: UL54:L516M;I521T +UL54 NC_006273 515 D E cidofovir 1.35 doi:doi.org/10.1016/j.jcv.2015.06.090,doi:doi.org/10.1016/j.antiviral.2025.106340 HerpesDRG Fold IC50 values: 1.6, 1.1; mean displayed, Test method: PRA,SEAP, Rule created at: 14/08/2023,25/09/2026 +UL54 NC_006273 515 D E foscarnet 2.2 doi:doi.org/10.1182/blood.V96.9.3286,doi:doi.org/10.1016/j.jcv.2015.06.090,doi:doi.org/10.1016/j.antiviral.2025.106340 HerpesDRG Fold IC50 values: 4.6, 1.1, 0.9; mean displayed, Test method: PRA or SEAP,PRA,SEAP, Rule created at: 17/11/2019,14/08/2023,25/09/2026, Co-mutation context in source: UL54:L516M;I521T +UL54 NC_006273 515 D E ganciclovir 2.03333 doi:doi.org/10.1182/blood.V96.9.3286,doi:doi.org/10.1016/j.jcv.2015.06.090,doi:doi.org/10.1016/j.antiviral.2025.106340 HerpesDRG Fold IC50 values: 2.7, 2.4, 1; mean displayed, Test method: PRA or SEAP,PRA,SEAP, Rule created at: 17/11/2019,14/08/2023,25/09/2026, Co-mutation context in source: UL54:L516M;I521T UL54 NC_006273 515 D G cidofovir 1 doi:doi.org/10.1086/375743 HerpesDRG Test method: PRA, Rule created at: 16/03/2020 UL54 NC_006273 515 D G foscarnet 1.2 doi:doi.org/10.1086/375743 HerpesDRG Test method: PRA, Rule created at: 16/03/2020 UL54 NC_006273 515 D G ganciclovir 1 doi:doi.org/10.1086/375743 HerpesDRG Test method: PRA, Rule created at: 16/03/2020 @@ -2119,15 +2125,18 @@ UL54 NC_006273 539 C R cidofovir 8.56667 doi:doi.org/10.1128/aac.00334-11,doi: UL54 NC_006273 539 C R foscarnet 0.6 doi:doi.org/10.1128/aac.00334-11,doi:doi.org/10.1016/j.antiviral.2022.105328 HerpesDRG Fold IC50 values: 0.7, 0.5; mean displayed, Test method: PRA, Rule created at: 17/11/2019,11/08/2025 UL54 NC_006273 539 C R ganciclovir 17.675 doi:doi.org/10.1128/aac.00334-11,doi:doi.org/10.1016/j.antiviral.2022.105328 HerpesDRG Fold IC50 values: 3.2, 6.3, 59, 2.2; mean displayed, Test method: PRA, Rule created at: 17/11/2019,11/08/2025, Co-mutation context in source: UL97:H520Q UL54 NC_006273 539 C R letermovir 1.1 doi:doi.org/10.1016/j.antiviral.2022.105328 HerpesDRG Test method: PRA, Rule created at: 11/08/2025 -UL54 NC_006273 542 D E cidofovir 12 doi:doi.org/10.1128/AAC.00062-13 HerpesDRG Test method: PRA, Rule created at: 23/11/2020 -UL54 NC_006273 542 D E foscarnet 1.7 doi:doi.org/10.1128/AAC.00062-13 HerpesDRG Test method: PRA, Rule created at: 23/11/2020 -UL54 NC_006273 542 D E ganciclovir 1.5 doi:doi.org/10.1128/AAC.00062-13 HerpesDRG Test method: PRA, Rule created at: 23/11/2020 +UL54 NC_006273 542 D E cidofovir 12.5 doi:doi.org/10.1128/AAC.00062-13,doi:doi.org/10.1016/j.antiviral.2025.106340 HerpesDRG Fold IC50 values: 12, 13; mean displayed, Test method: PRA,SEAP, Rule created at: 23/11/2020,25/09/2026 +UL54 NC_006273 542 D E foscarnet 1.1 doi:doi.org/10.1128/AAC.00062-13,doi:doi.org/10.1016/j.antiviral.2025.106340 HerpesDRG Fold IC50 values: 1.7, 0.5; mean displayed, Test method: PRA,SEAP, Rule created at: 23/11/2020,25/09/2026 +UL54 NC_006273 542 D E ganciclovir 2.5 doi:doi.org/10.1128/AAC.00062-13,doi:doi.org/10.1016/j.antiviral.2025.106340 HerpesDRG Fold IC50 values: 1.5, 3.5; mean displayed, Test method: PRA,SEAP, Rule created at: 23/11/2020,25/09/2026 UL54 NC_006273 543 A P cidofovir 16 doi:doi.org/10.1128/AAC.00922-18 HerpesDRG Test method: SEAP, Rule created at: 22/11/2019 UL54 NC_006273 543 A P foscarnet 0.6 doi:doi.org/10.1128/AAC.00922-18 HerpesDRG Test method: SEAP, Rule created at: 22/11/2019 UL54 NC_006273 543 A P ganciclovir 4.7 doi:doi.org/10.1128/AAC.00922-18 HerpesDRG Test method: SEAP, Rule created at: 22/11/2019 UL54 NC_006273 543 A S cidofovir 1 doi:doi.org/10.1093/infdis/jit654 HerpesDRG Test method: PRA, Rule created at: 16/03/2020 UL54 NC_006273 543 A S foscarnet 1 doi:doi.org/10.1093/infdis/jit654 HerpesDRG Test method: PRA, Rule created at: 16/03/2020 UL54 NC_006273 543 A S ganciclovir 1 doi:doi.org/10.1093/infdis/jit654 HerpesDRG Test method: PRA, Rule created at: 16/03/2020 +UL54 NC_006273 543 A V cidofovir 3.2 doi:doi.org/10.1016/j.antiviral.2025.106340 HerpesDRG Test method: SEAP, Rule created at: 25/09/2026 +UL54 NC_006273 543 A V foscarnet 0.7 doi:doi.org/10.1016/j.antiviral.2025.106340 HerpesDRG Test method: SEAP, Rule created at: 25/09/2026 +UL54 NC_006273 543 A V ganciclovir 2.1 doi:doi.org/10.1016/j.antiviral.2025.106340 HerpesDRG Test method: SEAP, Rule created at: 25/09/2026 UL54 NC_006273 544 V A cidofovir 1.1 doi:doi.org/10.1016/j.jcv.2011.01.004 HerpesDRG Test method: SEAP, Rule created at: 16/03/2020 UL54 NC_006273 544 V A foscarnet 0.9 doi:doi.org/10.1016/j.jcv.2011.01.004 HerpesDRG Test method: SEAP, Rule created at: 16/03/2020 UL54 NC_006273 544 V A ganciclovir 1 doi:doi.org/10.1016/j.jcv.2011.01.004 HerpesDRG Test method: SEAP, Rule created at: 16/03/2020 @@ -2182,6 +2191,9 @@ UL54 NC_006273 595 F I G00003_UL54_595_I_2 doi:doi.org/10.1128/aac.00334-11 H UL54 NC_006273 595 F I cidofovir 1.2 doi:doi.org/10.1128/aac.00334-11 HerpesDRG Test method: PRA, Rule created at: 17/11/2019 UL54 NC_006273 595 F I foscarnet 2 doi:doi.org/10.1128/aac.00334-11 HerpesDRG Test method: PRA, Rule created at: 17/11/2019 UL54 NC_006273 595 F I ganciclovir 1.3 doi:doi.org/10.1128/aac.00334-11 HerpesDRG Test method: PRA, Rule created at: 17/11/2019 +UL54 NC_006273 598 P S cidofovir 1.7 doi:doi.org/10.1016/j.antiviral.2025.106340 HerpesDRG Test method: SEAP, Rule created at: 25/09/2026 +UL54 NC_006273 598 P S foscarnet 0.7 doi:doi.org/10.1016/j.antiviral.2025.106340 HerpesDRG Test method: SEAP, Rule created at: 25/09/2026 +UL54 NC_006273 598 P S ganciclovir 1.9 doi:doi.org/10.1016/j.antiviral.2025.106340 HerpesDRG Test method: SEAP, Rule created at: 25/09/2026 UL54 NC_006273 600 H L cidofovir 2.8 doi:doi.org/10.3389/fmicb.2022.771978 HerpesDRG Fold IC50 values: 4.9, 0.7; mean displayed, Test method: PRA, Rule created at: 04/03/2022, Co-mutation context in source: UL54:T700A UL54 NC_006273 600 H L foscarnet 21.1 doi:doi.org/10.3389/fmicb.2022.771978 HerpesDRG Fold IC50 values: 5.2, 37; mean displayed, Test method: PRA, Rule created at: 04/03/2022, Co-mutation context in source: UL54:T700A UL54 NC_006273 600 H L ganciclovir 6.25 doi:doi.org/10.3389/fmicb.2022.771978 HerpesDRG Fold IC50 values: 11.1, 1.4; mean displayed, Test method: PRA, Rule created at: 04/03/2022, Co-mutation context in source: UL54:T700A @@ -2209,9 +2221,6 @@ UL54 NC_006273 676 S G ganciclovir 1.1 doi:doi.org/10.1128/jvi.72.7.5927-5936. UL54 NC_006273 692 A G cidofovir 0.9 doi:doi.org/10.1093/infdis/jit654 HerpesDRG Test method: PRA, Rule created at: 16/03/2020 UL54 NC_006273 692 A G foscarnet 1 doi:doi.org/10.1093/infdis/jit654 HerpesDRG Test method: PRA, Rule created at: 16/03/2020 UL54 NC_006273 692 A G ganciclovir 0.8 doi:doi.org/10.1093/infdis/jit654 HerpesDRG Test method: PRA, Rule created at: 16/03/2020 -UL54 NC_006273 692 A S cidofovir 1.7 doi:doi.org/10.1086/375743 HerpesDRG Test method: PRA, Rule created at: 16/03/2020 -UL54 NC_006273 692 A S foscarnet 3.3 doi:doi.org/10.1086/375743 HerpesDRG Test method: PRA, Rule created at: 16/03/2020 -UL54 NC_006273 692 A S ganciclovir 1.6 doi:doi.org/10.1086/375743 HerpesDRG Test method: PRA, Rule created at: 16/03/2020 UL54 NC_006273 694 V I ganciclovir 1 doi:doi.org/10.1097/TP.0b013e3181fdd9d2 HerpesDRG Test method: SEAP, Rule created at: 11/08/2025 UL54 NC_006273 694 V Q foscarnet 1.6 doi:doi.org/10.1128/AAC.00390-21 HerpesDRG Test method: GLuc reporter assay, Rule created at: 22/12/2021 UL54 NC_006273 694 V Q ganciclovir 0.5 doi:doi.org/10.1128/AAC.00390-21 HerpesDRG Test method: GLuc reporter assay, Rule created at: 22/12/2021 @@ -2280,6 +2289,9 @@ UL54 NC_006273 781 V I ganciclovir 1 doi:doi.org/10.1128/jvi.72.7.5927-5936.19 UL54 NC_006273 783 Q R cidofovir 0.9 doi:doi.org/10.1016/j.antiviral.2016.12.003 HerpesDRG Test method: SEAP, Rule created at: 16/03/2020 UL54 NC_006273 783 Q R foscarnet 1.7 doi:doi.org/10.1016/j.antiviral.2016.12.003 HerpesDRG Test method: SEAP, Rule created at: 16/03/2020 UL54 NC_006273 783 Q R ganciclovir 1.8 doi:doi.org/10.1016/j.antiviral.2016.12.003 HerpesDRG Test method: SEAP, Rule created at: 16/03/2020 +UL54 NC_006273 786 A V cidofovir 1 doi:doi.org/10.1016/j.antiviral.2025.106340 HerpesDRG Test method: SEAP, Rule created at: 25/09/2026 +UL54 NC_006273 786 A V foscarnet 1.1 doi:doi.org/10.1016/j.antiviral.2025.106340 HerpesDRG Test method: SEAP, Rule created at: 25/09/2026 +UL54 NC_006273 786 A V ganciclovir 1 doi:doi.org/10.1016/j.antiviral.2025.106340 HerpesDRG Test method: SEAP, Rule created at: 25/09/2026 UL54 NC_006273 787 V A cidofovir 1 doi:doi.org/10.1016/j.antiviral.2016.02.004,doi:doi.org/10.1093/infdis/jiz298 HerpesDRG Fold IC50 values: 0.7, 1.3; mean displayed, Test method: GFP fluorescence reduction assay,GLuc reporter assay, Rule created at: 23/11/2020,16/03/2020 UL54 NC_006273 787 V A foscarnet 4.225 doi:doi.org/10.1016/j.antiviral.2016.02.004,doi:doi.org/10.1093/infdis/jiz298 HerpesDRG Fold IC50 values: 3.2, 5.25; mean displayed, Test method: GFP fluorescence reduction assay,GLuc reporter assay, Rule created at: 23/11/2020,16/03/2020 UL54 NC_006273 787 V A ganciclovir 3.8 doi:doi.org/10.1016/j.antiviral.2016.02.004,doi:doi.org/10.1093/infdis/jiz298 HerpesDRG Fold IC50 values: 4.7, 2.9; mean displayed, Test method: GFP fluorescence reduction assay,GLuc reporter assay, Rule created at: 23/11/2020,16/03/2020 @@ -2381,15 +2393,24 @@ UL54 NC_006273 903 E G ganciclovir 1.1 doi:doi.org/10.1093/infdis/jit654 Herpe UL54 NC_006273 926 L V cidofovir 1.1 doi:doi.org/10.1128/aac.00334-11 HerpesDRG Test method: PRA, Rule created at: 16/03/2020 UL54 NC_006273 926 L V foscarnet 0.9 doi:doi.org/10.1128/aac.00334-11 HerpesDRG Test method: PRA, Rule created at: 16/03/2020 UL54 NC_006273 926 L V ganciclovir 1.3 doi:doi.org/10.1128/aac.00334-11 HerpesDRG Test method: PRA, Rule created at: 16/03/2020 -UL54 NC_006273 928 A T cidofovir resistant doi:doi.org/10.1093/infdis/jiac349 HerpesDRG Test method: PRA, Rule created at: 05/08/2023, no other mutations noted -UL54 NC_006273 928 A T foscarnet resistant doi:doi.org/10.1093/infdis/jiac349 HerpesDRG Test method: PRA, Rule created at: 05/08/2023, no other mutations noted -UL54 NC_006273 928 A T ganciclovir resistant doi:doi.org/10.1093/infdis/jiac349 HerpesDRG Test method: PRA, Rule created at: 05/08/2023, no other mutations noted +UL54 NC_006273 928 A T cidofovir resistant 1 doi:doi.org/10.1093/infdis/jiac349,doi:doi.org/10.1016/j.antiviral.2025.106340 HerpesDRG Test method: PRA,SEAP, Rule created at: 05/08/2023,25/09/2026, no other mutations noted +UL54 NC_006273 928 A T foscarnet resistant 0.9 doi:doi.org/10.1093/infdis/jiac349,doi:doi.org/10.1016/j.antiviral.2025.106340 HerpesDRG Test method: PRA,SEAP, Rule created at: 05/08/2023,25/09/2026, no other mutations noted +UL54 NC_006273 928 A T ganciclovir resistant 0.9 doi:doi.org/10.1093/infdis/jiac349,doi:doi.org/10.1016/j.antiviral.2025.106340 HerpesDRG Test method: PRA,SEAP, Rule created at: 05/08/2023,25/09/2026, no other mutations noted +UL54 NC_006273 928 A V cidofovir 1 doi:doi.org/10.1016/j.antiviral.2025.106340 HerpesDRG Test method: SEAP, Rule created at: 25/09/2026 +UL54 NC_006273 928 A V foscarnet 1.1 doi:doi.org/10.1016/j.antiviral.2025.106340 HerpesDRG Test method: SEAP, Rule created at: 25/09/2026 +UL54 NC_006273 928 A V ganciclovir 1 doi:doi.org/10.1016/j.antiviral.2025.106340 HerpesDRG Test method: SEAP, Rule created at: 25/09/2026 UL54 NC_006273 946 V L cidofovir 0.9 doi:doi.org/10.1128/aac.00334-11 HerpesDRG Test method: PRA, Rule created at: 17/11/2019 UL54 NC_006273 946 V L foscarnet 2.4 doi:doi.org/10.1128/aac.00334-11 HerpesDRG Test method: PRA, Rule created at: 17/11/2019 UL54 NC_006273 946 V L ganciclovir 1.1 doi:doi.org/10.1128/aac.00334-11 HerpesDRG Test method: PRA, Rule created at: 17/11/2019 UL54 NC_006273 947 K E cidofovir 1 doi:doi.org/10.1093/infdis/jit654 HerpesDRG Test method: PRA, Rule created at: 16/03/2020 UL54 NC_006273 947 K E foscarnet 1.1 doi:doi.org/10.1093/infdis/jit654 HerpesDRG Test method: PRA, Rule created at: 16/03/2020 UL54 NC_006273 947 K E ganciclovir 1 doi:doi.org/10.1093/infdis/jit654 HerpesDRG Test method: PRA, Rule created at: 16/03/2020 +UL54 NC_006273 949 E K cidofovir 1.6 doi:doi.org/10.1016/j.antiviral.2025.106340 HerpesDRG Test method: SEAP, Rule created at: 25/09/2026 +UL54 NC_006273 949 E K foscarnet 5.8 doi:doi.org/10.1016/j.antiviral.2025.106340 HerpesDRG Test method: SEAP, Rule created at: 25/09/2026 +UL54 NC_006273 949 E K ganciclovir 1.7 doi:doi.org/10.1016/j.antiviral.2025.106340 HerpesDRG Test method: SEAP, Rule created at: 25/09/2026 +UL54 NC_006273 949 E Q cidofovir 1.7 doi:doi.org/10.1016/j.antiviral.2025.106340 HerpesDRG Test method: SEAP, Rule created at: 25/09/2026 +UL54 NC_006273 949 E Q foscarnet 3.7 doi:doi.org/10.1016/j.antiviral.2025.106340 HerpesDRG Test method: SEAP, Rule created at: 25/09/2026 +UL54 NC_006273 949 E Q ganciclovir 1.4 doi:doi.org/10.1016/j.antiviral.2025.106340 HerpesDRG Test method: SEAP, Rule created at: 25/09/2026 UL54 NC_006273 951 E D cidofovir 1.2 doi:doi.org/10.1016/j.antiviral.2016.12.003 HerpesDRG Test method: SEAP, Rule created at: 16/03/2020 UL54 NC_006273 951 E D foscarnet 3.9 doi:doi.org/10.1016/j.antiviral.2016.12.003 HerpesDRG Test method: SEAP, Rule created at: 16/03/2020 UL54 NC_006273 951 E D ganciclovir 1.8 doi:doi.org/10.1016/j.antiviral.2016.12.003 HerpesDRG Test method: SEAP, Rule created at: 16/03/2020 @@ -2566,8 +2587,8 @@ UL97 NC_006273 342 F S foscarnet 1 doi:doi.org/10.1016/j.antiviral.2022.105328 UL97 NC_006273 342 F S ganciclovir 12.15 doi:doi.org/10.1128/AAC.00511-13,doi:doi.org/10.1016/j.antiviral.2022.105328 HerpesDRG Fold IC50 values: 7.8, 16.5; mean displayed, Test method: SEAP,GLuc, Rule created at: 17/11/2019,11/08/2025 UL97 NC_006273 342 F S letermovir 1 doi:doi.org/10.1016/j.antiviral.2022.105328 HerpesDRG Test method: GLuc, Rule created at: 11/08/2025 UL97 NC_006273 342 F S maribavir 26.5 doi:doi.org/10.1128/AAC.00511-13,doi:doi.org/10.1016/j.antiviral.2022.105328 HerpesDRG Fold IC50 values: 18, 35; mean displayed, Test method: SEAP,GLuc, Rule created at: 17/11/2019,11/08/2025 -UL97 NC_006273 342 F Y ganciclovir 5.93333 doi:doi.org/10.1016/j.antiviral.2019.104616,doi:doi.org/10.1016/j.antiviral.2021.105139 HerpesDRG Fold IC50 values: 6, 5.9, 5.9; mean displayed, Test method: SEAP, Rule created at: 21/11/2019,21/12/2021, Co-mutation context in source: UL97:H411Y -UL97 NC_006273 342 F Y maribavir 21.5667 doi:doi.org/10.1016/j.antiviral.2019.104616,doi:doi.org/10.1016/j.antiviral.2021.105139 HerpesDRG Fold IC50 values: 4.5, 56, 4.2; mean displayed, Test method: SEAP, Rule created at: 21/11/2019,21/12/2021, Co-mutation context in source: UL97:H411Y +UL97 NC_006273 342 F Y ganciclovir 6.075 doi:doi.org/10.1016/j.antiviral.2019.104616,doi:doi.org/10.1016/j.antiviral.2021.105139,doi:doi.org/10.1016/j.antiviral.2026.106536 HerpesDRG Fold IC50 values: 6, 5.9, 5.9, 6.5; mean displayed, Test method: SEAP, Rule created at: 21/11/2019,21/12/2021,25/09/2026, Co-mutation context in source: UL97:H411Y +UL97 NC_006273 342 F Y maribavir 17.4 doi:doi.org/10.1016/j.antiviral.2019.104616,doi:doi.org/10.1016/j.antiviral.2021.105139,doi:doi.org/10.1016/j.antiviral.2026.106536 HerpesDRG Fold IC50 values: 4.5, 56, 4.2, 4.9; mean displayed, Test method: SEAP, Rule created at: 21/11/2019,21/12/2021,25/09/2026, Co-mutation context in source: UL97:H411Y UL97 NC_006273 343 G A ganciclovir 8.2 doi:doi.org/10.1093/infdis/jiae469 HerpesDRG Fold IC50 values: 8.5, 7.9; mean displayed, Test method: SEAP, Rule created at: 31/10/2024, Co-mutation context in source: UL97:H411Y UL97 NC_006273 343 G A maribavir 199 doi:doi.org/10.1093/infdis/jiae469 HerpesDRG Fold IC50 values: 126, 272; mean displayed, Test method: SEAP, Rule created at: 31/10/2024, Co-mutation context in source: UL97:H411Y UL97 NC_006273 345 V I ganciclovir 1.3 doi:doi.org/10.1016/j.antiviral.2021.105139 HerpesDRG Test method: SEAP, Rule created at: 21/12/2021 @@ -2599,6 +2620,8 @@ UL97 NC_006273 397 L R foscarnet 1.15 doi:doi.org/10.1016/j.antiviral.2022.105 UL97 NC_006273 397 L R ganciclovir 1.625 doi:doi.org/10.1086/518514,doi:doi.org/10.1128/aac.46.8.2365-2372.2002,doi:doi.org/10.1016/j.antiviral.2022.105328,doi:doi.org/10.1016/j.jcv.2006.07.010 HerpesDRG Fold IC50 values: 1.5, 1, 1.4, 2.6; mean displayed, Test method: SEAP,PCR DNA hybridization assay,GLuc, Rule created at: 17/11/2019,07/08/2023,11/08/2025,18/08/2025 UL97 NC_006273 397 L R letermovir 1.1 doi:doi.org/10.1016/j.antiviral.2022.105328 HerpesDRG Test method: GLuc, Rule created at: 11/08/2025 UL97 NC_006273 397 L R maribavir 131.5 doi:doi.org/10.1086/518514,doi:doi.org/10.1128/aac.46.8.2365-2372.2002,doi:doi.org/10.1016/j.antiviral.2022.105328,doi:doi.org/10.1016/j.jcv.2006.07.010 HerpesDRG Fold IC50 values: 200, 34, 121, 171; mean displayed, Test method: SEAP,PCR DNA hybridization assay,GLuc, Rule created at: 17/11/2019,07/08/2023,11/08/2025,18/08/2025 +UL97 NC_006273 400 T M ganciclovir 1 doi:doi.org/10.1016/j.antiviral.2026.106536 HerpesDRG Test method: SEAP, Rule created at: 25/09/2026 +UL97 NC_006273 400 T M maribavir 0.9 doi:doi.org/10.1016/j.antiviral.2026.106536 HerpesDRG Test method: SEAP, Rule created at: 25/09/2026 UL97 NC_006273 405 L P ganciclovir 2.5 doi:doi.org/10.1128/AAC.00186-10 HerpesDRG Test method: SEAP, Rule created at: 17/11/2019 UL97 NC_006273 409 T M cidofovir 0.8 doi:doi.org/10.1016/j.antiviral.2022.105328 HerpesDRG Test method: GLuc, Rule created at: 11/08/2025 UL97 NC_006273 409 T M foscarnet 1.1 doi:doi.org/10.1016/j.antiviral.2022.105328 HerpesDRG Test method: GLuc, Rule created at: 11/08/2025 @@ -2669,7 +2692,11 @@ UL97 NC_006273 521 P L foscarnet 1.9 doi:doi.org/10.1016/j.antiviral.2022.1053 UL97 NC_006273 521 P L ganciclovir 31.5 doi:doi.org/10.1128/AAC.00511-13,doi:doi.org/10.1016/j.antiviral.2022.105328 HerpesDRG Fold IC50 values: 17, 46; mean displayed, Test method: SEAP,GLuc, Rule created at: 17/11/2019,11/08/2025 UL97 NC_006273 521 P L letermovir 1 doi:doi.org/10.1016/j.antiviral.2022.105328 HerpesDRG Test method: GLuc, Rule created at: 11/08/2025 UL97 NC_006273 521 P L maribavir 269.5 doi:doi.org/10.1128/AAC.00511-13,doi:doi.org/10.1016/j.antiviral.2022.105328 HerpesDRG Fold IC50 values: 445, 94; mean displayed, Test method: SEAP,GLuc, Rule created at: 17/11/2019,11/08/2025 +UL97 NC_006273 543 A T ganciclovir 1 doi:doi.org/10.1016/j.antiviral.2026.106536 HerpesDRG Test method: SEAP, Rule created at: 25/09/2026 +UL97 NC_006273 543 A T maribavir 1.1 doi:doi.org/10.1016/j.antiviral.2026.106536 HerpesDRG Test method: SEAP, Rule created at: 25/09/2026 UL97 NC_006273 550 M I ganciclovir 0.85 doi:doi.org/10.1086/505882 HerpesDRG Test method: PRA, Rule created at: 16/03/2020 +UL97 NC_006273 570 R Q ganciclovir 0.9 doi:doi.org/10.1016/j.antiviral.2026.106536 HerpesDRG Test method: SEAP, Rule created at: 25/09/2026 +UL97 NC_006273 570 R Q maribavir 1.1 doi:doi.org/10.1016/j.antiviral.2026.106536 HerpesDRG Test method: SEAP, Rule created at: 25/09/2026 UL97 NC_006273 582 A V ganciclovir 0.82 doi:doi.org/10.1086/505882 HerpesDRG Test method: PRA, Rule created at: 16/03/2020 UL97 NC_006273 587 H Y cidofovir 1 doi:doi.org/10.1128/AAC.49.7.2710-2715.2005 HerpesDRG Test method: SEAP, Rule created at: 16/03/2020 UL97 NC_006273 587 H Y foscarnet 0.8 doi:doi.org/10.1128/AAC.49.7.2710-2715.2005 HerpesDRG Test method: SEAP, Rule created at: 16/03/2020 @@ -2684,7 +2711,7 @@ UL97 NC_006273 592 C F ganciclovir 4 doi:doi.org/10.1002/jmv.2003 HerpesDRG Te UL97 NC_006273 592 C G cidofovir 1.4 doi:doi.org/10.1128/AAC.49.7.2710-2715.2005 HerpesDRG Test method: SEAP, Rule created at: 15/08/2023 UL97 NC_006273 592 C G cyclopropavir 3.3 doi:doi.org/10.1128/AAC.01259-10 HerpesDRG Test method: SEAP, Rule created at: 22/11/2019 UL97 NC_006273 592 C G foscarnet 1 doi:doi.org/10.1128/AAC.49.7.2710-2715.2005 HerpesDRG Test method: SEAP, Rule created at: 15/08/2023 -UL97 NC_006273 592 C G ganciclovir 3.10417 doi:doi.org/10.1128/AAC.00186-10,doi:doi.org/10.1016/j.antiviral.2019.104616,doi:doi.org/10.1128/AAC.01259-10,doi:doi.org/10.1016/j.antiviral.2021.105139,doi:doi.org/10.1128/AAC.00511-13,doi:doi.org/10.1086/338362,doi:doi.org/10.1128/jcm.00391-17,doi:doi.org/10.1128/AAC.49.7.2710-2715.2005,doi:doi.org/10.1093/infdis/jiae469,doi:doi.org/10.1097/TP.0b013e3181fdd9d2,doi:doi.org/10.1016/j.jcv.2006.07.010 HerpesDRG Fold IC50 values: 4.05, 3, 3, 3.1, 2.7, 2.5, 2.6, 3, 3, 3.2, 3.2, 3.9; mean displayed, Test method: SEAP,PRA, Rule created at: 17/11/2019,16/03/2020,22/11/2019,21/12/2021,07/08/2023,14/08/2023,15/08/2023,31/10/2024,11/08/2025,18/08/2025 +UL97 NC_006273 592 C G ganciclovir 3.13462 doi:doi.org/10.1128/AAC.00186-10,doi:doi.org/10.1016/j.antiviral.2019.104616,doi:doi.org/10.1128/AAC.01259-10,doi:doi.org/10.1016/j.antiviral.2021.105139,doi:doi.org/10.1128/AAC.00511-13,doi:doi.org/10.1086/338362,doi:doi.org/10.1128/jcm.00391-17,doi:doi.org/10.1128/AAC.49.7.2710-2715.2005,doi:doi.org/10.1093/infdis/jiae469,doi:doi.org/10.1097/TP.0b013e3181fdd9d2,doi:doi.org/10.1016/j.jcv.2006.07.010,doi:doi.org/10.1016/j.antiviral.2026.106536 HerpesDRG Fold IC50 values: 4.05, 3, 3, 3.1, 2.7, 2.5, 2.6, 3, 3, 3.2, 3.2, 3.9, 3.5; mean displayed, Test method: SEAP,PRA, Rule created at: 17/11/2019,16/03/2020,22/11/2019,21/12/2021,07/08/2023,14/08/2023,15/08/2023,31/10/2024,11/08/2025,18/08/2025,25/09/2026 UL97 NC_006273 592 C G maribavir 1.4 doi:doi.org/10.1016/j.jcv.2006.07.010 HerpesDRG Test method: SEAP, Rule created at: 18/08/2025 UL97 NC_006273 594 A E ganciclovir 3 doi:doi.org/10.1128/AAC.00186-10 HerpesDRG Test method: SEAP, Rule created at: 17/11/2019 UL97 NC_006273 594 A G ganciclovir 13.5 doi:doi.org/10.1016/S0166-0934(97)00093-1 HerpesDRG Test method: PRA, Rule created at: 17/11/2019 @@ -2711,11 +2738,15 @@ UL97 NC_006273 596 E G ganciclovir 2.3 doi:doi.org/10.1086/338362 HerpesDRG Te UL97 NC_006273 596 E Q ganciclovir 2.7 doi:doi.org/10.1093/infdis/jiad293 HerpesDRG Test method: SEAP, Rule created at: 29/11/2023 UL97 NC_006273 596 E Y ganciclovir 6.4 doi:doi.org/10.1016/j.jcv.2015.06.090 HerpesDRG Test method: PRA, Rule created at: 17/11/2019 UL97 NC_006273 597 N D ganciclovir 1.4 doi:doi.org/10.1002/jmv.21397 HerpesDRG Test method: SEAP, Rule created at: 16/03/2020 +UL97 NC_006273 598 G A ganciclovir 1.9 doi:doi.org/10.1016/j.antiviral.2026.106536 HerpesDRG Test method: SEAP, Rule created at: 25/09/2026 +UL97 NC_006273 598 G A maribavir 1.3 doi:doi.org/10.1016/j.antiviral.2026.106536 HerpesDRG Test method: SEAP, Rule created at: 25/09/2026 UL97 NC_006273 599 K E ganciclovir 1.2 doi:doi.org/10.1128/jcm.00391-17 HerpesDRG Test method: SEAP, Rule created at: 14/08/2023 UL97 NC_006273 599 K M aciclovir 1.6 doi:doi.org/10.1002/jmv.2003 HerpesDRG Test method: PRA, Rule created at: 14/08/2023, Reported as L599M compared to AD169 which has K599 and L600. Assuming the correct mutation is K599M UL97 NC_006273 599 K M cidofovir 1 doi:doi.org/10.1002/jmv.2003 HerpesDRG Test method: PRA, Rule created at: 14/08/2023, Reported as L599M compared to AD169 which has K599 and L600. Assuming the correct mutation is K599M UL97 NC_006273 599 K M foscarnet 3.8 doi:doi.org/10.1002/jmv.2003 HerpesDRG Test method: PRA, Rule created at: 14/08/2023, Reported as L599M compared to AD169 which has K599 and L600. Assuming the correct mutation is K599M UL97 NC_006273 599 K M ganciclovir 1.5 doi:doi.org/10.1002/jmv.2003 HerpesDRG Test method: PRA, Rule created at: 14/08/2023, Reported as L599M compared to AD169 which has K599 and L600. Assuming the correct mutation is K599M +UL97 NC_006273 599 K N ganciclovir 1.1 doi:doi.org/10.1016/j.antiviral.2026.106536 HerpesDRG Test method: SEAP, Rule created at: 25/09/2026 +UL97 NC_006273 599 K N maribavir 1.1 doi:doi.org/10.1016/j.antiviral.2026.106536 HerpesDRG Test method: SEAP, Rule created at: 25/09/2026 UL97 NC_006273 599 K R ganciclovir 0.9 doi:doi.org/10.1128/AAC.00186-10 HerpesDRG Test method: SEAP, Rule created at: 16/03/2020 UL97 NC_006273 599 K T ganciclovir 5.3 doi:doi.org/10.1016/S0166-3542(98)00051-5 HerpesDRG Test method: PRA, Rule created at: 17/11/2019 UL97 NC_006273 600 L I ganciclovir 1.4 doi:doi.org/10.1128/AAC.00186-10 HerpesDRG Test method: SEAP, Rule created at: 16/03/2020 @@ -2738,9 +2769,13 @@ UL97 NC_006273 610 I T ganciclovir 2.6 doi:doi.org/10.1016/j.jcv.2015.06.090 H UL97 NC_006273 613 A V ganciclovir 2.3 doi:doi.org/10.1016/j.antiviral.2013.09.026 HerpesDRG Test method: PRA, Rule created at: 17/11/2019 UL97 NC_006273 615 M V ganciclovir 1.1 doi:doi.org/10.1016/j.jcv.2010.01.009 HerpesDRG Test method: PRA, Rule created at: 14/08/2023 UL97 NC_006273 617 Y H ganciclovir 0.84 doi:doi.org/10.1086/505882 HerpesDRG Test method: PRA, Rule created at: 16/03/2020 +UL97 NC_006273 622 L M ganciclovir 1 doi:doi.org/10.1016/j.antiviral.2026.106536 HerpesDRG Test method: SEAP, Rule created at: 25/09/2026 +UL97 NC_006273 622 L M maribavir 0.9 doi:doi.org/10.1016/j.antiviral.2026.106536 HerpesDRG Test method: SEAP, Rule created at: 25/09/2026 UL97 NC_006273 623 G S ganciclovir 1.1 doi:doi.org/10.1128/AAC.00186-10 HerpesDRG Test method: SEAP, Rule created at: 16/03/2020 UL97 NC_006273 634 L Q ganciclovir 1.1 doi:doi.org/10.1086/338362 HerpesDRG Test method: PRA, Rule created at: 07/08/2023 UL97 NC_006273 655 E K ganciclovir 1.7 doi:doi.org/10.1128/jcm.02205-14 HerpesDRG Test method: GLuc reporter assay, Rule created at: 23/11/2020 UL97 NC_006273 659 T I ganciclovir 2.65 doi:doi.org/10.1128/AAC.00186-10,doi:doi.org/10.1172/jci117648 HerpesDRG Fold IC50 values: 1.3, 4; mean displayed, Test method: SEAP,PRA, Rule created at: 16/03/2020,14/08/2023 UL97 NC_006273 665 V I ganciclovir 1.1 doi:doi.org/10.1128/AAC.00186-10 HerpesDRG Test method: SEAP, Rule created at: 07/08/2023 UL97 NC_006273 674 A T ganciclovir 0.92 doi:doi.org/10.1086/505882 HerpesDRG Test method: PRA, Rule created at: 16/03/2020 +UL97 NC_006273 706 P S ganciclovir 1 doi:doi.org/10.1016/j.antiviral.2026.106536 HerpesDRG Test method: SEAP, Rule created at: 25/09/2026 +UL97 NC_006273 706 P S maribavir 1 doi:doi.org/10.1016/j.antiviral.2026.106536 HerpesDRG Test method: SEAP, Rule created at: 25/09/2026 diff --git a/databases/manifest.json b/databases/manifest.json index 120e8fa..a7a08e6 100644 --- a/databases/manifest.json +++ b/databases/manifest.json @@ -35,9 +35,9 @@ "publication_pmid": "39192205", "website": "https://github.com/ojcharles/herpesdrg-db", "description": "Comprehensive resource for human herpesvirus antiviral drug resistance genotyping.", - "maintainer_update": "2026-07-05", + "maintainer_update": "2026-09-29", "license": "MIT", - "tsv_checksum": "sha256:59f3c0fb4cc9ff8e3f013294de7b59fe956b930fe68ea5a94811d17b23c85fe6" + "tsv_checksum": "sha256:6d20f27b11b8a6616fc6b7f09d7825addaa8fbbf5d5f8a94a445ce818140dc5a" } }, {